1. Updated CINV Guidelines New Evidence for Change and Practical Issues

3. Making Progress in Controlling Emesis Efficacy and Effectiveness

4. Clinical Risk Factors for Emesis Personalizing Control

5. Evidence and Targets

6. Neurotransmitters and Antiemetic Pathways Targeting Key Pathways to Influence Emetic Control

7. Antiemetics in 2015 Practical Issues

8. NK1 RAs Approved* for Use as Antiemetics

9. Netupitant and NEPA

10. NEPA Phase 3 Trial Design

11. NEPA Phase 3 Trial CR Rates

12. DEX for Delayed Emesis Associated With 1 Dose of Cyclophosphamide or Anthracycline

14. Rolapitant A New NK1 RA

15. Rolapitant Phase 3 Trial Clinical Efficacy for Moderately Emetic Chemotherapy

16. Olanzapine as an Antiemetic Overview

17. Olanzapine 4-Agent (Including Cisplatin) Phase 2 Trial KCOG-G1301

18. Olanzapine 4-Agent Phase 3 Trial Alliance 221301

19. APR in Pediatrics, 2015 Phase 3 Randomized Trial; N = 302

20. Addition of APR in a 5-Day Cisplatin Trial Germ Cell Tumors

21. Benefit of NK1 RAs in Patients Receiving Carboplatin Phase 3 Trials

22. Perceptions and Reality Influence on Overuse and Underuse of Antiemetics

23. Two Studies Examining the Effectiveness of Guidelines Definitions

24. Adherence to NCCN Guidelines US Registry (INSPIRE) Study

25. Adherence to NCCN Guidelines US Registry (INSPIRE) Study: Results

26. Pan European Emesis Registry (PEER) Study Design Using MASCC Guidelines

27. Pan European Emesis Registry (PEER) Study Results Using MASCC Guidelines

28. Resource Use (Cycle 1) PEER Study Using MASCC Guidelines

29. Overview of Guidelines (NCCN/ASCO®/MASCC-ESMO) for Acute Nausea and Vomiting

31. Differences Among Guidelines ASCO®

32. Differences Among Guidelines NCCN and MASCC-ESMO

33. Recommendations for Refining Guidelines Acute Nausea and Vomiting

34. Recommendations for Refining Guidelines Delayed Nausea and Vomiting

35. Case 1 Breast Cancer

36. Case 2 Lung Cancer

37. Case 2 Lung Cancer (cont)

38. Case 2 Lung Cancer (cont)

39. Case 2: Antiemitic Options Lung Cancer (cont)

40. Improved Ability to Control Chemotherapy-Induced Emesis

41. Antiemetic Guidelines Conclusions

42. Multiple Roles for Supportive Care in Cancer

43. Abbreviations